What is SynDevRx?
SynDevRx is a biotechnology firm dedicated to revolutionizing cancer treatment through its innovative Metabo-Oncology platform. The company targets the metabolic pathways and angiogenic factors crucial to cancer progression. Its lead compound, Evexomostat, is engineered to address cancer patients experiencing metabolic complications and to amplify the efficacy of current therapeutic regimens. SynDevRx is actively validating its approach in clinical trials, with a particular focus on breast and prostate cancers, aiming to significantly improve patient outcomes for those with solid tumors.
How much funding has SynDevRx raised?
SynDevRx has raised a total of $18.4M across 3 funding rounds:
Unspecified
$569K
Debt
$16.3M
Debt
$1.5M
Unspecified (2009): $569K, investors not publicly disclosed
Debt (2012): $16.3M, investors not publicly disclosed
Debt (2017): $1.5M, investors not publicly disclosed
What's next for SynDevRx?
With substantial enterprise-level funding and a recent strategic investment, SynDevRx is poised for accelerated development and clinical validation. The company's focus on the intersection of metabolism and oncology represents a significant therapeutic frontier. Future endeavors will likely involve expanding clinical trial reach, potentially seeking regulatory approvals, and further refining Evexomostat's application across a broader spectrum of solid tumors. This capital infusion is expected to fuel research and development, bolster operational capacity, and support strategic partnerships to bring their novel treatments to market.
See full SynDevRx company page
